Advertisement

Secondary Primary Malignancies Rare After CAR T-Cell Immunotherapy

Mar 03, 2024

REFERENCES & ADDITIONAL READING

Ghilardi G, et al. T-Cell lymphoma and secondary primary malignancy risk after commercial car t-cell therapy. Nat Med. Published online January 24, 2024. doi:10.1038/s41591-024-02826-w

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
Advertisement